3147-32-8

Basic information

• Product Name: 2-(2-bromoethoxy)benzamide
• Synonyms: 2-(2-bromoethoxy)benzamide
• CAS NO: 3147-32-8
• Molecular Formula: C₉H₁₀BrNO₂
• Molecular Weight: 244.0852
• Mol File: 3147-32-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 371.7°C at 760 mmHg
• Flash Point: 178.6°C
• Appearance: /
• Density: 1.508g/cm³
• Vapor Pressure: 1.01E-05mmHg at 25°C
• Refractive Index: 1.584
• CAS DataBase Reference: 2-(2-bromoethoxy)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-bromoethoxy)benzamide(3147-32-8)
• EPA Substance Registry System: 2-(2-bromoethoxy)benzamide(3147-32-8)

Safety Data

• Hazardous Substances Data: 3147-32-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C9H10BrNO2/c10-5-6-13-8-4-2-1-3-7(8)9(11)12/h1-4H,5-6H2,(H2,11,12)

Upstream product

• 106-93-4 ethylene dibromide 
• 65-45-2 salicylamide 

Downstream Products

• 58932-30-2 2-(2-aminoethoxy)benzamide 
• 1295624-38-2 2-{2-[4-(2-methoxyphenyl)piperazin-1-yl]ethoxy}benzamide 
• 58756-99-3 1-[2-(2-carbamoyl-phenyloxy)-ethyl-amino]-3-(3-methyl-pyridin-2-yloxy)-2-propanol 
• 3384-41-6 N-<2-(2-Carbamoyl-phenoxy)-aethyl>-3-<2-methoxy-phenoxy>-propylamin 
• 1310877-88-3 2-{2-[4-(3-methoxyphenyl)piperazin-1-yl]ethoxy}benzamide 
• 1310877-89-4 2-{2-[4-(2-chlorophenyl)piperazin-1-yl]ethoxy}benzamide 
• 1310877-86-1 2-{2-[4-(3-methylphenyl) piperazin-1-yl]ethoxy}benzamide 
• 1310877-87-2 2-{2-[4-(4-methylphenyl) piperazin-1-yl]ethoxy}benzamide 
• 167846-76-6 2-[2-(4-phenylpiperazin-1-yl)ethoxy]benzamide 
• 264186-17-6 2-[2-(3-Phenoxy-propylamino)-ethoxyl]-benzamide hydrochloride 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

Evaluation of 1-arylpiperazine derivative of hydroxybenzamides as 5-HT 1A and 5-HT7 serotonin receptor ligands: An experimental and molecular modeling approach

The synthesis and evaluation as 5-HT1A and 5-HT7 serotonin receptor ligands of the two sets of O-substituted hydroxybenzamides, structurally related to 2-{3-[4-(2-methoxyphenyl)piperazin-1-yl]propoxy} benzamide (1), (Ki 5-